Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Valeo Pharma stock price, quote, forecast and news

VPH.TO
CA91915B1085
A2PLB4

Price

0.07
Today +/-
-0.00
Today %
-7.41 %
P

Valeo Pharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Valeo Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Valeo Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Valeo Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Valeo Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Valeo Pharma Stock Price History

DateValeo Pharma Price
9/17/20240.07 undefined
9/16/20240.07 undefined
9/13/20240.07 undefined
9/12/20240.08 undefined
9/11/20240.06 undefined
9/10/20240.06 undefined
9/9/20240.06 undefined
9/6/20240.06 undefined
9/5/20240.06 undefined
9/4/20240.07 undefined
9/3/20240.07 undefined
8/30/20240.07 undefined
8/29/20240.07 undefined
8/28/20240.08 undefined
8/27/20240.08 undefined
8/26/20240.08 undefined
8/23/20240.08 undefined
8/21/20240.08 undefined

Valeo Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Valeo Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Valeo Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Valeo Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Valeo Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Valeo Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Valeo Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Valeo Pharma’s growth potential.

Valeo Pharma Revenue, EBIT and net profit per share

DateValeo Pharma RevenueValeo Pharma EBITValeo Pharma Net Income
2028e178.07 M undefined93.96 M undefined16.79 M undefined
2027e186.41 M undefined81.65 M undefined39.49 M undefined
2026e156.42 M undefined55.8 M undefined27.15 M undefined
2025e70.4 M undefined-661,550 undefined-13.95 M undefined
2024e58.68 M undefined-6.5 M undefined-26.91 M undefined
202353.91 M undefined-17.23 M undefined-27.81 M undefined
202227.75 M undefined-19.11 M undefined-25.75 M undefined
202113.56 M undefined-12.57 M undefined-14.23 M undefined
20207.47 M undefined-4.3 M undefined-4.76 M undefined
20196.58 M undefined-3.74 M undefined-3.62 M undefined
20184.38 M undefined-2.43 M undefined-2.44 M undefined
20171.28 M undefined-2.65 M undefined-3.62 M undefined
2016985,710 undefined-2.54 M undefined-1.28 M undefined

Valeo Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e
014671327535870156186178
--300.0050.0016.6785.71107.6996.309.4320.69122.8619.23-4.30
---16.6714.2923.0822.2224.53-----
00011361300000
-2-2-2-3-4-12-19-17-60558193
--200.00-50.00-50.00-57.14-92.31-70.37-32.08-10.34-35.2643.5552.25
-1-3-2-3-4-14-25-27-26-13273916
-200.00-33.3350.0033.33250.0078.578.00-3.70-50.00-307.6944.44-58.97
31.431.435.6549.5957.9169.9380.8686.1200000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Valeo Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Valeo Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (k)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
               
0.2100.010.342.842.0422.57.5
0000.381.011.475.236.42
000232211325203144
000.090.560.887.689.9810.25
0.060.050.050.140.470.832.620.93
0.260.050.161.655.4112.3540.5325.24
0.350.330.310.30.612.142.252.66
4.594.59000000
000003242030
0.51.671.983.864.956.5415.4813.3
00000000
0046.9900000
0.862.012.344.165.55917.9415.96
1.122.062.55.8110.9621.3558.4741.21
               
0.410.414.668.8315.0224.6226.3631.7
0.110.190.270.591.612.74.414.58
600.04-3,018.75-6,101.24-9,118-13,144-24,941-51,530-79,297
-0.16-0.19-0.19-0.33-0.42-0.322.912.68
00000000
0.96-2.6-1.37-0.023.072.05-17.85-40.34
0.731.312.054.384.019.9612.4611.42
000010326600
000.050.10.10.212.094.19
00.980.850000.742.79
000.100.064.90.051.88
0.732.293.054.484.2815.3315.3420.27
2.363.461.4613.22.7760.6560.5
00000000
213.19247.4241.46351416873127771
2.573.711.71.353.623.6460.7761.27
3.364.755.837.8918.9876.1181.54
4.263.43.395.8110.9621.0358.2741.21
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Valeo Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Valeo Pharma's financial health and stability.

Assets

Valeo Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Valeo Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Valeo Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Valeo Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
-1-3-2-3-4-14-25-27
00000012
000000-10
0100-2-1-114
-10001285
00000027
00000000
-1-1-1-2-5-12-28-15
0-100-1-3-6-5
2000-1-3-6-5
20000000
00000000
121023192
000371303
0213915546
-20000-1340
00000000
00002020-14
-2.46-2.65-1.66-3.25-6.7-15.78-35.39-21.25
00000000

Valeo Pharma stock margins

The Valeo Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Valeo Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Valeo Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Valeo Pharma's sales revenue. A higher gross margin percentage indicates that the Valeo Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Valeo Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Valeo Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Valeo Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Valeo Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Valeo Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Valeo Pharma Margin History

Valeo Pharma Gross marginValeo Pharma Profit marginValeo Pharma EBIT marginValeo Pharma Profit margin
2028e24.26 %52.77 %9.43 %
2027e24.26 %43.8 %21.18 %
2026e24.26 %35.67 %17.36 %
2025e24.26 %-0.94 %-19.82 %
2024e24.26 %-11.07 %-45.86 %
202324.26 %-31.96 %-51.58 %
202222.64 %-68.88 %-92.8 %
202129.17 %-92.72 %-104.99 %
202018.49 %-57.56 %-63.73 %
201921.3 %-56.82 %-54.96 %
201819.01 %-55.42 %-55.62 %
201741.52 %-207.26 %-283.27 %
201640.19 %-257.19 %-129.5 %

Valeo Pharma Stock Sales Revenue, EBIT, Earnings per Share

The Valeo Pharma earnings per share therefore indicates how much revenue Valeo Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Valeo Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Valeo Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Valeo Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Valeo Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Valeo Pharma Revenue, EBIT and net profit per share

DateValeo Pharma Sales per ShareValeo Pharma EBIT per shareValeo Pharma Earnings per Share
2028e1.8 undefined0 undefined0.17 undefined
2027e1.89 undefined0 undefined0.4 undefined
2026e1.59 undefined0 undefined0.28 undefined
2025e0.71 undefined0 undefined-0.14 undefined
2024e0.59 undefined0 undefined-0.27 undefined
20230.63 undefined-0.2 undefined-0.32 undefined
20220.34 undefined-0.24 undefined-0.32 undefined
20210.19 undefined-0.18 undefined-0.2 undefined
20200.13 undefined-0.07 undefined-0.08 undefined
20190.13 undefined-0.08 undefined-0.07 undefined
20180.12 undefined-0.07 undefined-0.07 undefined
20170.04 undefined-0.08 undefined-0.12 undefined
20160.03 undefined-0.08 undefined-0.04 undefined

Valeo Pharma business model

Valeo Pharma Inc is a pharmaceutical company that was founded in 2003. It is based in Montreal, Canada and its stocks are traded on the Toronto Stock Exchange. The company specializes in the development, manufacturing, and marketing of innovative pharmaceutical and medical products to help patients in Canada and around the world. Valeo Pharma's business model is based on identifying unmet medical needs, particularly in niche markets where there is a demand for innovative solutions. The company recognizes that there are difficulties for patients and healthcare professionals in finding specific medications suitable for their treatment needs in these niche markets. Valeo Pharma aims to fill this gap by developing innovative products tailored to the specific needs of patients and professionals, differentiating itself from other standard products. Valeo Pharma operates in two main business areas: Pharmaceuticals and OTC - Over-the-Counter. The pharmaceutical division of Valeo Pharma focuses on the development of drugs for the treatment of diseases that are currently inadequately treated. Their products in this area include drugs for the treatment of neurology, oncology, infectious diseases, dermatology, and psychiatry. Valeo Pharma's OTC division specializes in the development of products for self-medication and disease prevention. Their products in this area include pain relief products, cold and cough treatments, and general health support. Some of Valeo Pharma's key products include Blexten, an antihistamine for the treatment of seasonal and perennial allergic rhinitis as well as chronic idiopathic urticaria, and Redesca, a product for the prevention of blood clots and reducing the risk of thrombosis in patients with various medical conditions. Valeo Pharma has formed various partnerships with leading pharmaceutical companies around the world to bring its products to market. Through these partnerships, the company can expand its reach and offer exclusive products to its customers in different regions. Valeo Pharma is committed to research and development of new products that meet the needs of patients and healthcare professionals. The company invests in the development of active substances that treat diseases that are currently inadequately treated or have no effective medical treatments available. Overall, Valeo Pharma has established itself as a leading pharmaceutical company in Canada, focusing on providing innovative products to improve the health and well-being of patients. The company has a strong presence in the Canadian and international pharmaceutical industry and aims to expand its business through the development and marketing of innovative products and the formation of further strategic partnerships with pharmaceutical companies. Valeo Pharma is one of the most popular companies on Eulerpool.com.

Valeo Pharma SWOT Analysis

Strengths

Valeo Pharma Inc has several strengths that contribute to its success in the pharmaceutical industry. These strengths include:

  • Strong portfolio of high-quality pharmaceutical products
  • Effective research and development capabilities
  • Well-established distribution network
  • Experienced and skilled management team
  • Strong financial position

Weaknesses

Despite its strengths, Valeo Pharma Inc also faces certain weaknesses that need to be addressed in order to maintain a competitive edge:

  • Relatively small market share compared to larger competitors
  • Limited presence in international markets
  • Dependence on a few key suppliers
  • High production costs
  • Lack of diversification in product offerings

Opportunities

Valeo Pharma Inc has promising opportunities that it can leverage to drive growth and expand its market presence:

  • Increasing demand for pharmaceutical products globally
  • Growing aging population and healthcare needs
  • Potential for strategic partnerships and collaborations
  • Expansion into emerging markets with untapped growth potential
  • Advancements in technology for drug development

Threats

Valeo Pharma Inc should also be aware of the potential threats that could hinder its performance and profitability:

  • Intense competition from larger and more established pharmaceutical companies
  • Regulatory changes and increasing scrutiny of the industry
  • Rapidly evolving market dynamics and consumer preferences
  • Economic uncertainties and market volatility
  • Possible patent expiration and generic drug competition

Valeo Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Valeo Pharma historical P/E ratio, EBIT, and P/S ratio.

Valeo Pharma shares outstanding

The number of shares was Valeo Pharma in 2023 — This indicates how many shares 86.117 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Valeo Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Valeo Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Valeo Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Valeo Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Valeo Pharma.

Valeo Pharma latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.05 -0.05  (0.99 %)2024 Q2
3/31/2024-0.08 -0.08  (-5.54 %)2024 Q1
12/31/2023-0.07 -0.1  (-52.21 %)2023 Q4
9/30/2023-0.07 -0.07  (-6.54 %)2023 Q3
6/30/2023-0.08 -0.08  (-5.54 %)2023 Q2
3/31/2023-0.08 -0.08  (0.99 %)2023 Q1
12/31/2022-0.05 -0.13  (-157.43 %)2022 Q4
9/30/2022-0.06 -0.06  (-7.91 %)2022 Q3
6/30/2022-0.06 -0.06  (0.99 %)2022 Q2
3/31/2022-0.04 -0.07  (-97.74 %)2022 Q1
1
2

Valeo Pharma list of shareholders

%
Name
Stocks
Change
Date
7.23874 % Investissement Québec7,142,8577,142,8578/31/2023
25.71359 % Manitex Capital Inc25,372,98703/22/2024
2.36271 % Leger (Marc Francois)2,331,41403/22/2024
16.39360 % 100079 Canada, Inc.16,176,455-46,2963/22/2024
1.71689 % Simcor Canada Holdings, Inc.1,694,1451,694,1453/22/2024
0.65059 % Trudeau (Michel Claude)641,97237,0374/27/2023
0.52427 % Hogue (Vincent)517,323264,9172/27/2023
0.18317 % Saviuk (Steven)180,74503/22/2024
0.17735 % Raich (Robert)175,00003/22/2024
0.04692 % Mackay (Richard J)46,29603/22/2024
1
2

Valeo Pharma Executives and Management Board

Mr. Steven Saviuk64
Valeo Pharma President, Chief Executive Officer, Director (since 2003)
Compensation 273,630
Ms. Nathalie Therrien
Valeo Pharma Vice President - Quality Assurance and Regulatory Affairs
Compensation 205,683
Mr. Luc Mainville60
Valeo Pharma Chief Financial Officer, Senior Vice President
Compensation 194,982
Ms. Helen Saviuk
Valeo Pharma Vice President - Operations
Compensation 187,112
Mr. Marc Leger64
Valeo Pharma Director
Compensation 30,176
1
2
3

Most common questions regarding Valeo Pharma

What values and corporate philosophy does Valeo Pharma represent?

Valeo Pharma Inc represents a values-driven corporate philosophy centered on innovation, integrity, and patients' well-being. As a pharmaceutical company, Valeo Pharma prioritizes product quality and safety, striving to provide effective healthcare solutions. With a focus on patient care, Valeo Pharma aims to improve the lives of individuals by developing and commercializing innovative pharmaceutical products. Through its dedication to research and development, the company demonstrates a commitment to advancing healthcare technologies and addressing unmet medical needs. Valeo Pharma's corporate philosophy encompasses responsibility, transparency, and collaboration, enabling them to deliver trusted and impactful healthcare solutions to enhance patient outcomes.

In which countries and regions is Valeo Pharma primarily present?

Valeo Pharma Inc is primarily present in Canada.

What significant milestones has the company Valeo Pharma achieved?

Valeo Pharma Inc has achieved several significant milestones. Firstly, the company successfully obtained Health Canada approval for many of its innovative pharmaceutical products, allowing them to be commercially available in the Canadian market. Additionally, Valeo Pharma Inc has established partnerships and collaborations with renowned pharmaceutical companies, facilitating the expansion of their product offerings and market reach. The company has also demonstrated strong financial performance, displaying consistent revenue growth and profitability. Furthermore, Valeo Pharma Inc has made continuous efforts to enhance its portfolio by acquiring promising pharmaceutical assets and actively pursuing research and development initiatives.

What is the history and background of the company Valeo Pharma?

Valeo Pharma Inc is a pharmaceutical company with a rich history and background. Founded in 2003, Valeo Pharma has become a leading player in the Canadian healthcare industry. The company focuses on the development, licensing, and distribution of innovative prescription and over-the-counter (OTC) pharmaceutical products. Valeo Pharma is committed to providing high-quality medicines and improving patient outcomes. With a strong management team and strategic partnerships, the company has experienced significant growth and expansion. Valeo Pharma's dedication to innovation, excellence, and patient care has made it a trusted name in the pharmaceutical sector.

Who are the main competitors of Valeo Pharma in the market?

The main competitors of Valeo Pharma Inc in the market include various pharmaceutical companies such as Pfizer, GlaxoSmithKline, Novartis, and Johnson & Johnson.

In which industries is Valeo Pharma primarily active?

Valeo Pharma Inc is primarily active in the healthcare and pharmaceutical industries.

What is the business model of Valeo Pharma?

The business model of Valeo Pharma Inc revolves around the development, acquisition, and commercialization of innovative pharmaceutical products. As a specialty pharmaceutical company, Valeo Pharma focuses on providing unique therapeutic solutions to meet unmet medical needs. They collaborate with global pharmaceutical companies to establish partnerships and licensing agreements for bringing novel products to the Canadian market. Valeo Pharma's strategic approach combines in-house product development, leveraging its regulatory and clinical expertise, with a strong emphasis on product acquisition and commercialization. By continuously expanding its portfolio and reaching partnerships, Valeo Pharma aims to deliver innovative healthcare solutions to patients in Canada.

What is the P/E ratio of Valeo Pharma 2024?

The Valeo Pharma P/E ratio is -0.21.

What is the P/S ratio of Valeo Pharma 2024?

The Valeo Pharma P/S ratio is 0.1.

What is the AlleAktien quality score of Valeo Pharma?

The AlleAktien quality score for Valeo Pharma is 4/10.

What is the revenue of Valeo Pharma 2024?

The expected Valeo Pharma revenue is 58.68 M CAD.

How high is the profit of Valeo Pharma 2024?

The expected Valeo Pharma profit is -26.91 M CAD.

What is the business model of Valeo Pharma

Valeo Pharma Inc. is a Canadian pharmaceutical company based in Quebec that specializes in the development, manufacturing, and marketing of products in various therapy areas. The company aims to provide innovative solutions for unmet medical needs and is committed to improving the health and well-being of patients. The company is divided into four main business segments: Valeo Pharma Canada, Valeo Pharma International, Valeo Distribution, and Valeo Health. Valeo Pharma Canada is the core business of the company and focuses on marketing prescription drugs and consumer products, including pain and inflammation medications, cardiovascular and renal drugs, antidepressants, antipsychotics, and vitamins. The company markets several innovative products and has established strong relationships with key players in the Canadian healthcare industry. Valeo Pharma International is the international division of the company, specializing in expanding into new markets outside of Canada. The company leverages its deep knowledge of the global pharmaceutical and medical markets to build successful business relationships and market innovative products worldwide. Valeo Distribution is the distribution arm of the company, focusing on distributing the products of Valeo Pharma Canada and Valeo Pharma International. The company works closely with physicians, pharmacies, and health authorities to ensure effective distribution of the products. It also provides logistics and distribution services for other partner companies. Valeo Health is the company's newest business segment, specializing in the development of wellness and lifestyle products. The company has developed a unique line of products aimed at improving consumer well-being and health, and enhancing their quality of life. This includes weight management products, dietary supplements, and skincare products. Overall, Valeo Pharma Inc. has a broad portfolio of products that enables it to operate at various levels of the healthcare industry. The company is committed to improving healthcare in Canada and beyond by developing and marketing innovative products that help patients achieve their health goals. With strong leadership and a dedicated team, Valeo Pharma Inc. is well positioned to grow in the pharmaceutical industry and create value for its customers and shareholders.

What is the Valeo Pharma dividend?

Valeo Pharma pays a dividend of 0 CAD distributed over payouts per year.

How often does Valeo Pharma pay dividends?

The dividend cannot currently be calculated for Valeo Pharma or the company does not pay out a dividend.

What is the Valeo Pharma ISIN?

The ISIN of Valeo Pharma is CA91915B1085.

What is the Valeo Pharma WKN?

The WKN of Valeo Pharma is A2PLB4.

What is the Valeo Pharma ticker?

The ticker of Valeo Pharma is VPH.TO.

How much dividend does Valeo Pharma pay?

Over the past 12 months, Valeo Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Valeo Pharma is expected to pay a dividend of 0 CAD.

What is the dividend yield of Valeo Pharma?

The current dividend yield of Valeo Pharma is .

When does Valeo Pharma pay dividends?

Valeo Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Valeo Pharma?

Valeo Pharma paid dividends every year for the past 0 years.

What is the dividend of Valeo Pharma?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Valeo Pharma located?

Valeo Pharma is assigned to the '-' sector.

Wann musste ich die Aktien von Valeo Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Valeo Pharma from 9/19/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 9/19/2024.

When did Valeo Pharma pay the last dividend?

The last dividend was paid out on 9/19/2024.

What was the dividend of Valeo Pharma in the year 2023?

In the year 2023, Valeo Pharma distributed 0 CAD as dividends.

In which currency does Valeo Pharma pay out the dividend?

The dividends of Valeo Pharma are distributed in CAD.

All fundamentals about Valeo Pharma

Our stock analysis for Valeo Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Valeo Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.